Acer Therapeutics stock plummets 80 percent on FDA rejection

The FDA rejected Acer's application this week, tasking the company with conducting new trials of the drug, called edsivo, before re-submitting it approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.